Therapeutic Use of LPI, a Staphylococcal Lectin Pathway Inhibitor in Inflammatory Diseases

VAN WAMEL, Willem Jan Bastiaan ; Rooijakkers, Suzan Huberdian Maria ; et al.

2011

Online Patent

Zugriff:

View record in USPTO Patent Applications (Volltext)

The invention relates to nucleic acid molecules encoding (poly)peptides having LPI (Lectin Pathway Inhibitor) activity, to recombinant vectors harboring such molecules, and the host cells carrying the vectors. The invention further relates to methods for preparing recombinant (poly)peptides having LPI activity and to the use of such recombinant (poly)peptides having LPI activity for diagnosis, prophylaxis and treatment, such as the treatment of inflammation reactions. In addition the invention provides therapeutic and diagnostic compositions comprising as the active ingredient the (poly)peptide having LPI activity.

Titel:	Therapeutic Use of LPI, a Staphylococcal Lectin Pathway Inhibitor in Inflammatory Diseases
Autor/in / Beteiligte Person:	VAN WAMEL, Willem Jan Bastiaan ; Rooijakkers, Suzan Huberdian Maria ; Van Kessel, Cornelis Petrus Maria ; Van Strijp, Johannes Antonius Gerardus
Link:	View record in USPTO Patent Applications (Volltext)
Veröffentlichung:	2011
Medientyp:	Patent
Sonstiges:	Nachgewiesen in: USPTO Patent Applications Sprachen: English Document Number: 20110118194 Publication Date: May 19, 2011 Appl. No: 12/939872 Application Filed: November 04, 2010 Assignees: UMC Utrecht Holding B.V. (CM Utrecht, NL) Claim: 1.-48. (canceled) Claim: 49. A method of treating or preventing an acute or chronic inflammatory reaction in a subject, the method comprising administering a peptide or polypeptide to said subject for the treatment of said acute and chronic inflammatory reaction in said subject, wherein said peptide or polypeptide is encoded by a nucleotide sequence corresponding to a sequence selected from: a) a nucleotide sequence comprising a fragment of the sequence set forth in SEQ ID NO:1; b) a nucleotide sequence having at least about 90% nucleotide sequence identity to the nucleotide sequence set forth in SEQ ID NO:1; c) a nucleotide sequence encoding a peptide or polypeptide comprising the amino acid set forth in SEQ ID NO:3; d) a nucleotide sequence that hybridizes under stringent hybridization to any one of the nucleotide sequences (a), (b), or (c); and e) a nucleotide sequence complementary to any one of the nucleotide sequences (a), (b), (c), or (d); and wherein the peptide or polypeptide has lectin pathway inhibitory (LPI) activity and reduces mannose binding lectin associated serine protease-2 (MASP2) dependent cleavage of complement protein C2 into C2a and C2b. Claim: 50. The method of claim 49, wherein the nucleotide sequence comprising a fragment of the sequence set forth in SEQ ID NO:1 corresponds to nucleotides 1-490 of SEQ ID NO:1. Claim: 51. The method of claim 49, wherein the nucleotide sequence comprising a fragment of the sequence set forth in SEQ ID NO:1 corresponds to nucleotides 41-490 of SEQ ID NO:1. Claim: 52. The method of claim 49, wherein the nucleotide sequence comprising a fragment of the sequence set forth in SEQ ID NO:1 corresponds to nucleotides 125-490 of SEQ ID NO:1. Claim: 53. The method of claim 49, wherein the nucleotide sequence has at least about 90% nucleotide sequence identity to the nucleotide sequence set forth in SEQ ID NO:1. Claim: 54. The method of claim 49, wherein the stringent hybridization conditions comprise overnight hybridization at 42° C. in 5×SSC and washing at 65° C. in 0.1×SSC. Claim: 55. The method of claim 49, wherein the peptide or polypeptide is administered in a therapeutic composition. Current U.S. Class: 514/212 Current International Class: 61; 61

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.